Interactions between midazolam and remifentanil during monitored anesthesia care

Area of Science:

• Anesthesiology
• Pharmacology
• Clinical Trials

Background:

• Remifentanil, an ultra-short-acting opioid, is a potential intravenous adjuvant for local anesthesia during monitored anesthesia care (MAC).
• Optimal remifentanil dosing, interactions with midazolam, and recovery profiles require further investigation for ambulatory procedures.

Purpose of the Study:

• To evaluate the safety and efficacy of remifentanil alone and with varying midazolam doses during MAC.
• To determine remifentanil dose requirements and recovery characteristics in combination with midazolam.

Main Methods:

• Eighty-one women undergoing breast biopsy were randomized into four groups (placebo, midazolam 2, 4, or 8 mg) followed by remifentanil infusion.
• Sedation (OAA/S scale), pain, vital signs, amnesia, and recovery (Aldrete score, discharge times) were monitored.
• Postoperative side effects and satisfaction were assessed via telephone interview.

Main Results:

• Midazolam increased sedation levels dose-dependently.
• Remifentanil plus higher midazolam doses (4-8 mg) caused greater respiratory rate reduction.
• Light sedation (OAA/S 1-3) correlated with increased pruritus and PONV, prolonging discharge.

Conclusions:

• Remifentanil alone was insufficient for MAC sedation.
• A combination of 0.05-0.1 mcg/kg/min remifentanil and 2 mg midazolam provided effective sedation and analgesia in ASA I-II patients.
• Sedation level impacts intraoperative pruritus and PONV incidence in outpatients receiving midazolam and remifentanil.